Plasma β-amyloid 40 levels are positively associated with mortality risks in the elderly

Alzheimer's and Dementia

Volumn 11, Issue 6, 2015, Pages 672-680

  Gabelle, Audrey ^a,b   Schraen, Susanna ^c,d,e   Gutierrez, Laure Anne ^a,f   Pays, Cecile ^a,f   Rouaud, Olivier ^g   Buée, Luc ^c,d,e   Touchon, Jacques ^a,f   Helmer, Catherine ^e   Lambert, Jean Charles ^c,d,e,h   Berr, Claudine ^a,b,f  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b UNIV MONTPELLIER   (France)

^c UNIV LILLE   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e INSERM   (France)

^f Montpellier 1 University   (France)

^g DIJON UNIVERSITY HOSPITAL   (France)

^h INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Aging; Cystatin C; Frailty; Mild cognitive impairment due to Alzheimer's disease; Mortality risks; Plasma amyloid markers

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; CYSTATIN C; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); CST3 PROTEIN, HUMAN; PEPTIDE FRAGMENT;

AGE; AGED; ARTICLE; CASE STUDY; CLINICAL EVALUATION; COGNITIVE DEFECT; COHORT ANALYSIS; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; DIAGNOSTIC KIT; DIET; EDUCATION; FEMALE; FRAIL ELDERLY; GERIATRICS; HAZARD RATIO; HIGH RISK POPULATION; HUMAN; HUMAN EXPERIMENT; MALE; MORTALITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK FACTOR; STATISTICAL ANALYSIS; VASCULAR DISEASE; BLOOD; CASE CONTROL STUDY; EPIDEMIOLOGY; FOLLOW UP; FRANCE; KAPLAN MEIER METHOD; RANDOMIZATION; RISK;

AGED; AMYLOID BETA-PEPTIDES; CASE-CONTROL STUDIES; CYSTATIN C; FEMALE; FOLLOW-UP STUDIES; FRANCE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MORTALITY; PEPTIDE FRAGMENTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RANDOM ALLOCATION; RISK;

EID: 84931570421     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2014.04.515     Document Type: Article

References (51)

1. R. Mayeux, L.S. Honig, M.X. Tang, J. Manly, Y. Stern, N. Schupf, et al. Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk Neurology 61 2003 1185 1190
2. M. van Oijen, A. Hofman, H.D. Soares, P.J. Koudstaal, and M.M. Breteler Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study Lancet Neurol 5 2006 655 660
3. J.C. Lambert, S. Schraen-Maschke, F. Richard, N. Fievet, O. Rouaud, C. Berr, et al. Association of plasma amyloid beta with risk of dementia: the prospective Three-City Study Neurology 73 2009 847 853
4. T.T. Seppala, S.K. Herukka, T. Hanninen, S. Tervo, M. Hallikainen, H. Soininen, et al. Plasma Abeta42 and Abeta40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study J Neurol Neurosurg Psychiatry 81 2010 1123 1127
5. J.K. Lui, S.M. Laws, Q.X. Li, V.L. Villemagne, D. Ames, B. Brown, et al. Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL study of aging J Alzheimers Dis 20 2010 1233 1242
6. K. Yaffe, A. Weston, N.R. Graff-Radford, S. Satterfield, E.M. Simonsick, S.G. Younkin, et al. Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline JAMA 305 2011 261 266
7. A. Gabelle, F. Richard, L.A. Gutierrez, S. Schraen, F. Delva, O. Rouaud, et al. Plasma amyloid-beta levels and prognosis in incident dementia cases of the 3-City Study J Alzheimers Dis 33 2013 381 391
8. M. Hernandez-Guillamon, P. Delgado, A. Penalba, D. Rodriguez-Luna, C.A. Molina, A. Rovira, et al. Plasma beta-amyloid levels in cerebral amyloid angiopathy-associated hemorrhagic stroke Neurodegener Dis 10 2012 320 323
9. B. Dubois, H.H. Feldman, C. Jacova, J.L. Cummings, S.T. Dekosky, P. Barberger-Gateau, et al. Revising the definition of Alzheimer's disease: a new lexicon Lancet Neurol 9 2010 1118 1127
10. C.R. Jack Jr., D.S. Knopman, W.J. Jagust, L.M. Shaw, P.S. Aisen, M.W. Weiner, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade Lancet Neurol 9 2010 119 128
11. C.C. Smith, and D.J. Betteridge Plasma beta-amyloid (A beta) 40 concentration, lipid status and age in humans Neurosci Lett 367 2004 48 50
12. H. Fukumoto, M. Tennis, J.J. Locascio, B.T. Hyman, J.H. Growdon, and M.C. Irizarry Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels Neurology 60 2003 958 964
13. A.L. Metti, J.A. Cauley, H.N. Ayonayon, T.B. Harris, C. Rosano, J.D. Williamson, et al. The demographic and medical correlates of plasma aβ40 and aβ42 Alzheimer Dis Assoc Disord 27 2013 244 249
14. J.C. Lambert, J. Dallongeville, K.A. Ellis, S. Schraen-Maschke, J. Lui, S. Laws, et al. Association of plasma Aβ peptides with blood pressure in the elderly PLoS One 6 2011 e18536
15. A.L. Metti, J.A. Cauley, A.B. Newman, H.N. Ayonayon, L.C. Barry, L.M. Kuller, et al. Plasma beta amyloid level and depression in older adults J Gerontol A Biol Sci Med Sci 68 2013 74 79
16. I. Blasko, G. Kemmler, S. Jungwirth, I. Wichart, S. Weissgram, K. Jellinger, et al. Prospective study on association between plasma amyloid beta-42 and atherosclerotic risk factors J Neural Transm 118 2011 663 672
17. Y. Gu, N. Schupf, S.A. Cosentino, J.A. Luchsinger, and N. Scarmeas Nutrient intake and plasma beta-amyloid Neurology 78 2012 1832 1840
18. Vascular factors and risk of dementia: design of the Three-City Study and baseline characteristics of the study population Neuroepidemiology 22 2003 316 325
19. S. Artero, M.L. Ancelin, F. Portet, A. Dupuy, C. Berr, J.F. Dartigues, et al. Risk profiles for mild cognitive impairment and progression to dementia are gender specific J Neurol Neurosurg Psychiatry 79 2008 979 984
20. L.P. Fried, C.M. Tangen, J. Walston, A.B. Newman, C. Hirsch, J. Gottdiener, et al. Frailty in older adults: evidence for a phenotype J Gerontol A Biol Sci Med Sci 56 2001 M146 M156
21. J.A. Avila-Funes, C. Helmer, H. Amieva, P. Barberger-Gateau, M. Le Goff, K. Ritchie, et al. Frailty among community-dwelling elderly people in France: the three-city study J Gerontol A Biol Sci Med Sci 63 2008 1089 1096
22. G. Breton, M. Froissart, N. Janus, V. Launay-Vacher, C. Berr, C. Tzourio, et al. Inappropriate drug use and mortality in community-dwelling elderly with impaired kidney function - the Three-City population-based study Nephrol Dial Transplant 26 2011 2852 2859
23. World Health Organisation International Classification of Diseases and Related Health Problems (ICD-10) 1992 WHO
24. A. Alperovitch, M. Bertrand, E. Jougla, J.S. Vidal, P. Ducimetiere, C. Helmer, et al. Do we really know the cause of death of the very old? Comparison between official mortality statistics and cohort study classification Eur J Epidemiol 24 2009 669 675
25. A.C. Thiebaut, and J. Benichou Choice of time-scale in Cox's model analysis of epidemiologic cohort data: a simulation study Stat Med 23 2004 3803 3820
26. A. Pilotto, F. Rengo, N. Marchionni, D. Sancarlo, A. Fontana, F. Panza, et al. Comparing the prognostic accuracy for all-cause mortality of frailty instruments: a multicentre 1-year follow-up in hospitalized older patients PLoS One 7 2012 e29090
27. C. Cano, R. Samper-Ternent, S. Al Snih, K. Markides, and K.J. Ottenbacher Frailty and cognitive impairment as predictors of mortality in older Mexican Americans J Nutr Health Aging 16 2012 142 147
28. C. Bilotta, L. Bergamaschini, P. Nicolini, A. Case, G. Pina, S.V. Rossi, et al. Frailty syndrome diagnosed according to the Study of Osteoporotic Fractures criteria and mortality in older outpatients suffering from Alzheimer's disease: a one-year prospective cohort study Aging Ment Health 16 2012 273 280
29. J.M. Jacobs, A. Cohen, E. Ein-Mor, Y. Maaravi, and J. Stessman Frailty, cognitive impairment and mortality among the oldest old J Nutr Health Aging 15 2011 678 682
30. C. Annweiler, R. Bataille, N. Ferriere, D. Douillet, B. Fantino, and O. Beauchet Plasma beta-2 microglobulin as a marker of frailty in older adults: a pilot study J Gerontol A Biol Sci Med Sci 66 2011 1077 1079
31. N. Fujimoto, N. Wada, M. Akiyama, S. Tajima, A. Ishibashi, and S. Miyakawa Coexistence of beta2 microglobulin and lambda light chain in amyloid fibrils of dialysis-unrelated plasma cell dyscrasia-associated systemic amyloidosis Br J Dermatol 147 2002 549 553
32. T.B. Drueke Beta2-microglobulin and amyloidosis Nephrol Dial Transplant 15 Suppl 1 2000 17 24
33. S. Debette, J.C. Lambert, J. Gariepy, N. Fievet, C. Tzourio, J.F. Dartigues, et al. New insight into the association of apolipoprotein E genetic variants with carotid plaques and intima-media thickness Stroke 37 2006 2917 2923
34. T.A. Kokjohn, G.D. Van Vickle, C.L. Maarouf, W.M. Kalback, J.M. Hunter, I.D. Daugs, et al. Chemical characterization of pro-inflammatory amyloid-beta peptides in human atherosclerotic lesions and platelets Biochimica et biophysica acta 1812 2011 1508 1514
35. M. Gomis, T. Sobrino, A. Ois, M. Millan, A. Rodriguez-Campello, N. Perez de la Ossa, et al. Plasma beta-amyloid 1-40 is associated with the diffuse small vessel disease subtype Stroke 40 2009 3197 3201
36. A.H. Warfel, D. Zucker-Franklin, B. Frangione, and J. Ghiso Constitutive secretion of cystatin C (gamma-trace) by monocytes and macrophages and its downregulation after stimulation J Exp Med 166 1987 1912 1917
37. G. Filler, A. Bokenkamp, W. Hofmann, T. Le Bricon, C. Martinez-Bru, and A. Grubb Cystatin C as a marker of GFR - history, indications, and future research Clin Biochem 38 2005 1 8
38. J. Sundelof, J. Arnlov, E. Ingelsson, J. Sundstrom, S. Basu, B. Zethelius, et al. Serum cystatin C and the risk of Alzheimer disease in elderly men Neurology 71 2008 1072 1079
39. W. Mi, S.S. Jung, H. Yu, S.D. Schmidt, R.A. Nixon, P.M. Mathews, et al. Complexes of amyloid-beta and cystatin C in the human central nervous system J Alzheimers Dis 18 2009 273 280
40. M. Sastre, M. Calero, M. Pawlik, P.M. Mathews, A. Kumar, V. Danilov, et al. Binding of cystatin C to Alzheimer's amyloid beta inhibits in vitro amyloid fibril formation Neurobiol Aging 25 2004 1033 1043
41. K. Maruyama, S. Ikeda, T. Ishihara, D. Allsop, and N. Yanagisawa Immunohistochemical characterization of cerebrovascular amyloid in 46 autopsied cases using antibodies to beta protein and cystatin C Stroke 21 1990 397 403
42. M.L. Selenica, X. Wang, L. Ostergaard-Pedersen, A. Westlind-Danielsson, and A. Grubb Cystatin C reduces the in vitro formation of soluble Abeta1-42 oligomers and protofibrils Scand J Clin Lab Invest 67 2007 179 190
43. S.A. Kaeser, M.C. Herzig, J. Coomaraswamy, E. Kilger, M.L. Selenica, D.T. Winkler, et al. Cystatin C modulates cerebral beta-amyloidosis Nat Genet 39 2007 1437 1439
44. J.B. Toledo, H. Vanderstichele, M. Figurski, P.S. Aisen, R.C. Petersen, M.W. Weiner, et al. Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI Acta neuropathologica 122 2011 401 413
45. N. Le Bastard, J. Leurs, W. Blomme, P.P. De Deyn, and S. Engelborghs Plasma amyloid-beta forms in Alzheimer's disease and non-Alzheimer's disease patients J Alzheimers Dis 21 2010 291 301
46. J.K. Lui, S.M. Laws, Q.X. Li, V.L. Villemagne, D. Ames, B. Brown, et al. Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL Study of Aging J Alzheimers Dis 20 2010 1233 1242
47. J. Dumurgier, C. Paquet, S. Benisty, C. Kiffel, C. Lidy, F. Mouton-Liger, et al. Inverse association between CSF Aβ 42 levels and years of education in mild form of Alzheimer's disease: the cognitive reserve theory Neurobiol Dis 40 2010 456 459
48. P. Sjogren, W. Becker, E. Warensjo, E. Olsson, L. Byberg, I.B. Gustafsson, et al. Mediterranean and carbohydrate-restricted diets and mortality among elderly men: a cohort study in Sweden Am J Clin Nutr 92 2010 967 974
49. E.L. de Hollander, M. Van Zutphen, R.P. Bogers, W.J. Bemelmans, and L.C. De Groot The impact of body mass index in old age on cause-specific mortality J Nutr Health Aging 16 2012 100 106
50. H.O. Svendsen, and J. Mosbech Mortality of alcoholic liver cirrhosis. Diagnostic background for statistics concerning cause of death Ugeskrift for laeger 138 1976 1910 1911
51. Z. Arvanitakis, J.A. Lucas, L.H. Younkin, S.G. Younkin, and N.R. Graff-Radford Serum creatinine levels correlate with plasma amyloid beta protein Alzheimer disease and associated disorders 16 2002 187 190